| CTRI Number |
CTRI/2025/04/085220 [Registered on: 21/04/2025] Trial Registered Prospectively |
| Last Modified On: |
27/10/2025 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Observational |
|
Type of Study
|
Cross Sectional Study |
| Study Design |
Other |
|
Public Title of Study
|
A study on cutaneous resident memory T cell population in contact dermatitis |
|
Scientific Title of Study
|
A study on cutaneous resident memory T cell population in contact dermatitis and its correlation with the type of contact dermatitis, duration, severity and recurrence of the disease |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Haritha Prasanth |
| Designation |
Junior Resident |
| Affiliation |
Amala Institute of Medical Sciences |
| Address |
Department of Dermatology,
Amala Institute of Medical Sciences, Amala nagar,Thrissur Amala Institute of Medical Sciences, Amala nagar,Thrissur Thrissur KERALA 680555 India |
| Phone |
9496489136 |
| Fax |
|
| Email |
harithaprasanth254@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Sebastian Criton |
| Designation |
Professor and HOD |
| Affiliation |
Amala Institute of Medical Sciences |
| Address |
Department of Dermatology,
Amala Institute of Medical Sciences, Amala nagar,Thrissur Amala Institute of Medical Sciences, Amala nagar,Thrissur Thrissur KERALA 680555 India |
| Phone |
9447009990 |
| Fax |
|
| Email |
criton@thecriton.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Sebastian Criton |
| Designation |
Professor and HOD |
| Affiliation |
Amala Institute of Medical Sciences |
| Address |
Department of Dermatology,
Amala Institute of Medical Sciences, Amala nagar,Thrissur Amala Institute of Medical Sciences, Amala nagar,Thrissur Thrissur KERALA 680555 India |
| Phone |
9447009990 |
| Fax |
|
| Email |
criton@thecriton.com |
|
|
Source of Monetary or Material Support
|
| ICMR financial support for the ICMR MD thesis for the 2023 batch-reg |
|
|
Primary Sponsor
|
| Name |
Haritha Prasanth |
| Address |
Junior Resident
Department of Dermatology,
Amala Institute of Medical Sciences, Amala nagar,Thrissur |
| Type of Sponsor |
Other [Self] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Haritha Prasanth |
Amala Institute of Medical Sciences |
Department of Dermatology,
Amala Institute of Medical Sciences, Amala nagar,Thrissur Thrissur KERALA |
9496489136
harithaprasanth254@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| IEC, Amala Institute of Medical Sciences |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: L23||Allergic contact dermatitis, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Comparator Agent |
NIL |
NIL |
| Intervention |
NIL |
NIL |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
60.00 Year(s) |
| Gender |
Both |
| Details |
Patients clinically diagnosed with contact dermatitis by qualified dermatologists, who give consent to participate in the study. |
|
| ExclusionCriteria |
| Details |
1. Patients with other skin diseases like psoriasis, vitiligo, cutaneous lupus erythematosus, alopecia areata, fixed drug eruption, melanoma, lichen planus
2. Patients with endogenous eczema
3. Patients who had taken systemic steroids, JAK inhibitors and immunomodulators in the past one month
4. Patients on topical steroids and topical calcineurin inhibitors for past 1 month
5. Patients who had undergone other modalities of treatment – Ayurveda/Homeopathy/Unani/Siddha in the past 1 month
|
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
| comparison of memory T cell number(density) between lesional and normal skin in patients with contact dermatitis |
at baseline |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| EASI score, Patch Test, comparing memory T cell number between type of contact dermatitis, duration, severity and recurrence of the disease |
at the same time of sample collection |
|
|
Target Sample Size
|
Total Sample Size="26" Sample Size from India="26"
Final Enrollment numbers achieved (Total)= "27"
Final Enrollment numbers achieved (India)="27" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
01/05/2025 |
| Date of Study Completion (India) |
01/08/2025 |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Date Missing |
|
Estimated Duration of Trial
|
Years="1" Months="6" Days="0" |
Recruitment Status of Trial (Global)
Modification(s)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Completed |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
This is a cross-sectional study wherein 26 consecutive patients clinically diagnosed as contact dermatitis satisfying the inclusion and exclusion criteria attending OPD of dermatology department of Amala Institute of Medical Sciences who consent for the study are selected. A detailed history will be taken and examination will be conducted. Under aseptic precaution and local anaesthesia 4mm punch biopsy will be taken from lesional and normal skin. Patients will be subjected to patch testing. The biopsy sections will be subjected to IHC staining for memory T cells using CD103 marker stain. Memory T cell population will be calculated by counting number of stained cells per 5 continuous high power field focused. Exploring more about cutaneous resident memory T cells and their role in the pathophysiology of contact dermatitis paves way for the development of various therapeutic options and thereby helping to prevent recurrences. |